Form D · Biotechnology
Affinivax, Inc.
Cambridge, MA · CIK 0001726931
Offering snapshot reported Jan 13, 2021 · SEC filing
- Reported sold
- $226M Offering amount: $226M
- Investors reported
- 27 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 7, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 13, 2021 | Initial | $225,999,698 | No comparison | 27 | SEC filing |
| Jan 5, 2018 | Initial | $6,987,455 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-386253
Source: Form D, filed Jan 13, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven Altschuler | Director |
| Steven Brugger | Director, Executive |
| Andrew Hack | Director |
| Frances Heller | Director |
| Richard Malley | Director |
| Robert More | Director |
| George Siber | Director |
| Kamran Tavangar | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
301 Binney Street
Cambridge, MA, 02142
Cambridge, MA, 02142